Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01860963 · ClinicalTrials.gov registry record · NA
Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 310
- Enrollment target
NCT01860963: Completed NA study, sponsored by Stanford University.
NCT01860963 is a NA study that has completed, run by Stanford University. The registered enrollment target is 310 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01860963, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 310 participants
- Enrollment target
Study Summary
This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.
Interventions
- PROCEDURE Anal Pap smear and HPV DNA testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01860963
The ClinicalTrials.gov registry entry for NCT01860963 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anal Pap smear and HPV DNA testing is the first listed.
NCT01860963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01860963 about?
NCT01860963 is a clinical study titled "Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls". This study is designed to establish the prevalence of anal squamous intraepithelial lesion (ASIL) in patients with inflammatory bowel disease (IBD) and healthy controls.
What is the current status of trial NCT01860963?
This trial is currently completed. It is a NA study. The enrollment target is 310 participants. The study started on 2010-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01860963?
The interventions under investigation include: Anal Pap smear and HPV DNA testing (PROCEDURE).
Who is sponsoring clinical trial NCT01860963?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.